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Abstract: The world urgently needs effective antiviral approaches against emerging viruses, as shown by the coronavirus disease 2019
(COVID-19) pandemic, which has become an exponentially growing health crisis. Scientists from diverse backgrounds have directed
their efforts towards identifying key features of SARS-CoV-2 and clinical manifestations of COVID-19 infection. Reports of more
transmissible variants of SARS-CoV-2 also raise concerns over the possibility of an explosive trajectory of the pandemic, so scientific
attention should focus on developing new weapons to help win the fight against coronaviruses that may undergo further mutations in
the future. Drosophila melanogaster offers a powerful and potential in vivo model that can significantly increase the efficiency of drug
screening for viral and bacterial infections. Thanks to its genes with functional human homologs, Drosophila could play a significant
role in such gene-editing studies geared towards designing vaccines and antiviral drugs for COVID-19. It can also help rectify current
drawbacks of CRISPR-based therapeutics like off-target effects and delivery issues, representing another momentous step forward in
healthcare. Here I present an overview of recent literature and the current state of knowledge, explaining how it can open up new
avenues for Drosophila in our battle against infectious diseases.
Key words: Drosophila melanogaster, COVID-19 pandemic, SARS-CoV-2, human disease models, CRISPR-Cas systems

1. Coronavirus disease 2019 (COVID-19) pandemic: a
landmark in the history of infectious diseases
Epidemics of infectious disease caused by viruses and
bacteria have been haunting humanity ever since the
very earliest settlements, claiming millions of lives and
disrupting communities across the globe. Even today,
communicable diseases like lower respiratory infections,
malaria, HIV/AIDS, and diarrheal diseases still rank
among leading causes of death in many parts of the
world. And for over a year now, we have been confronted
with yet another global pandemic, which is caused by a
novel coronavirus commonly known as SARS-CoV-2.
According to the most recent figures published by World
Health Organization (WHO, 2021), there have been over
100 million confirmed cases of COVID-19, with a death
toll reaching over 2 million since the beginning of the
outbreak in December 2019–March 2021. It is predicted
that many millions of people will become infected before
an effective vaccine has been developed and a widespread
immunization campaign can be implemented, which will
continue to put healthcare centres and staff under heavy
strain and result in further loss of life.

In the face of an exponentially growing health crisis,
scientists from diverse fields have been making every
possible effort to identify the key genomic features of SARSCoV-2 and clinical manifestations of COVID-19 infection,
including acute pneumonia, respiratory distress, cytokine
storms, and damage to multiple organs (Guan et al., 2020;
Jiang et al., 2020). However, there are still several questions
and challenges that needs to be addressed, which include
factors influencing virus infectivity, mode of transmission,
routes of infection, genes responsible for susceptibility and
infection severity, protective role of immune system, and
host-virus interactome (i.e. interactions between viral and
host proteins). As new symptoms and complications related
to COVID-19 infection continue to appear at different
locations, we must constantly update our knowledge and
provide guidance to reduce the uncertainty surrounding
the infection and tackle the spread of current pandemic.
The novel coronavirus SARS-CoV-2 responsible for
COVID-19 pandemic actually belongs to Coronaviridae
family consisting of positive-strand RNA viruses, which
cause respiratory tract infections in mammals through
direct cytotoxic effects and inflammatory reactions
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mediated by cytokines in the host immune system (Liu
et al., 2020). So far seven coronavirus species have been
identified to cause infection among humans, which
include MERS-CoV and SARS-CoV. Since coronaviruses
can evolve rapidly and be transmitted to humans from a
wide range of animal hosts like rodents and bats known
as high-risk viral reservoirs, scientific efforts should focus
on developing new methods and weapons to facilitate the
fight against coronaviruses that may undergo mutations
in the future (Mohd et al., 2016). Although SARS-CoV-2
has been observed to mutate significantly more slowly as
compared to HIV or influenza viruses (Callaway et al.,
2020), a recent paper reported that more transmissible
forms of SARS-CoV-2 with distinct genomic sequences are
becoming the dominant forms across Europe (Korber et
al., 2020). A new variant of concern, called lineage B.1.1.7,
was reported in UK in December 2020, with enhanced
transmissibility and potential to expand the predicted
trajectory of the pandemic (Galloway et al., 2021). At
present, the clinical outcomes of such variants appear
to show no difference from that of the original strains,
but we know that a higher rate of human-to-human
transmission means more COVID-19 cases and greater
number of people requiring clinical attention. This could
further increase the burden on our already-strained health
systems and ultimately lead to more deaths. Therefore, we
need aggressive pan-coronavirus solutions to mitigate the
spread of the virus, design therapeutic agents and effective
vaccines, as well as diagnostic tools for widespread testing;
otherwise global death toll could reach terrifying peaks in
the coming months (Galloway, 2021).
2. In vivo model organisms in COVID-19 research
Although in vitro studies using human cell lines or
organoids offer invaluable insight into the virus infection,
viral life cycle, and replication, the intricate pathogenesis
of COVID-19 disease may only be explained through
recreating systemic virus-host interactions in animal
models (Takayama, 2020). Ever since the outbreak of
COVID-19 pandemic, several animal models have been
employed in experiments to decipher the codes of the
infection or to test potential antiviral drugs. A study,
for example, used rhesus monkeys (Macaca mulatta)
to understand whether primary infection could protect
patients from the risk of reinfection, finding that the
monkeys reexposed to the virus had no recurring
COVID-19 infection (Bao et al., 2020a). Another study
using nine adult rhesus macaques found that the infected
animals developed a near-complete immunity against
SARS-CoV-2 rechallenge (Chandrashekar et al., 2020).
Even though higher mammals like monkeys and apes play
a crucial role in enhancing our knowledge about human
physiology and are still our key allies in solving puzzling
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problems related to infectious diseases like COVID-19, we
should note that animal scarcity and ethical issues severely
restrict the use of such models, with small samples often
consisting of one or two monkeys. Naturally, this limits
the generalizability of their results to wider populations or
situations and complicates the interpretation of the data.
Mice are also among favourite animal models widely
employed by virus researchers to identify pathological
characteristics of viruses on account of their wellestablished immune system, breeding capabilities, and
accessibility. However, a study from the early phase of the
pandemic showed low angiotensin-converting enzyme
2 (ACE2)-binding affinity, one of the key determinants
of infectivity, in mice and rats (Wan et al., 2020), thus
limiting our ability to create an effective COVID-19
infection in such animals. On the other hand, some
researchers used transgenic mice with expressed human
ACE2 receptor and successfully infected these mice with
SARS-CoV-2, observing virus replication in the lungs and
reduced pulmonary function (Bao et al., 2020b; Winkler
et al., 2020). While they suggested the use of transgenic
mice as a suitable model organism for testing immunity
and antiviral measures against COVID-19, the low supply
of mice with humanized ACE2 receptors in laboratories
due to the restrictions of the pandemic may limit its
widespread use in experiments (Soldatov et al., 2020).
In the search of alternative models, one study found that
the golden hamster (Mesocricetus auratus) could be used
in research on pathogenesis and transmission routes of
SARS-CoV-2 (Chan et al., 2020). Ever since the discovery
that ferrets can be infected by influenza virus by Smith
et al. have been used as ideal animal models in influenza
studies because they show symptoms similar to those of
infected humans and they can transmit the virus to other
ferrets (Smith et al., 1933). In this regard, Kim et al. studied
SARS-CoV-2 transmission, replication, and viral shedding
in a small group of ferrets (Mustela putorius furo) and
reported certain limitations of this model, such as infected
ferrets exhibiting only mild symptoms and lower viral
loads in the lungs (Kim et al., 2020). Furthermore, recent
studies have revealed that SARS-CoV-2 replicated poorly
in domesticated animals including pigs, dogs, chickens,
and ducks, while it could cause infection in cats through
airborne transmission (Shi et al., 2020). However, the
number of animals used in such experiments was rather
low (as low as five or six animals) due to ethical concerns
over euthanasia of healthy animals after the experiments.
As for larger animals, Cynomolgus macaques (Macaca
fascicularis), a species native to Southeast Asia, have been
proposed as another suitable animal model in identifying
critical pathways of coronavirus infections, since they
were permissive to such infections and exhibited certain
symptoms comparable to those associated with COVID-19
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(Rockx et al., 2020). In an effort to develop protective or
therapeutic measures against the explosive spread of the
pandemic, scientists also carried out vaccine and drug
trials in rhesus macaques to test whether such agents could
treat or prevent SARS-CoV-2 pneumonia (Van Doremalen
et al., 2020; Williamson et al., 2020; Yu et al., 2020). Even
though such larger animal models appear to be the ideal
choice in elucidating the key interactions between the
virus and human hosts, their relatively slow reproductive
capacity and growth rates tend to restrict their extensive
use.
3. Potential application of Drosophila as a test model in
viral infections
Due to growing ethical concerns and animal rights
movements over the use of mammals like rodents or
nonhuman primates in scientific experiments, researchers
have been seeking out an ideal and simpler model organism
that would allow them to circumvent the process of the
ethics committee approval, which may be frustratingly
difficult in some cases. In this regard, a species of fruit fly
called Drosophila melanogaster has been gaining scholarly
attention and acceptance as a potential in vivo model in
recent biological, genetic, and medical research. In fact,
this fruit fly might have become one of the best-known
eukaryotic organisms in the world since it was the first
complex organism whose whole genome was sequenced
(Adams et al., 2000). A few years later, after the mapping
of human genome was completed by the Human Genome
Project in 2013, scientists began to identify homologies
between the two genomes, which helped establish its role as
a reliable model to study human disease processes. Today,
discoveries related to human biology and genetics are
described in fruit flies and then translated to mammalian
organisms (Pandey and Nichols, 2011).

Drosophila offers a range of advantages over the use
of mammals in experiments, including much lower
production costs, a very rapid life cycle, high productive
capacity, and far simpler genetics with only four pairs
of chromosomes (Jennings, 2011). A female fly can
produce up to 2000 genetically similar offspring during
her lifetime (2 months), whereas most rodent models are
able to generate only a handful of offspring every 12 to
16 weeks. In addition, about 75% of the genes playing a
role in known human diseases have at least one functional
homolog in the genetic code of Drosophila, so any new
findings in the fruit fly often translate well into human
health sciences (Lloyd and Taylor, 2010). The protein
sequence similarity between Drosophila and mammals is
normally at about 40%, though it could be as high as 90%
in conserved functional domains (Pandey and Nichols,
2011). Above all, in spite of many obvious anatomic
differences between humans and fruit flies, they share
basic principles of cell biology, such as regulation of gene
expression, formation of synapses between neurons, cell
proliferation, differentiation into specialized cell types,
cell signalling, apoptosis and autophagy. Furthermore, the
response of these flies to various medications influencing
their central nervous system is comparable to the effects
observed in mammalian systems (Andretic et al., 2008).
The immune signalling pathways that respond to cytokines
are remarkably conserved from fly to man. Therefore, D.
melanogaster, provides an excellent platform for studying
the biology and function of cytokines. Categories of some
human viruses studied using Drosophila as a model in
vivo organism is shown in Table. Also, Drosophila as an
in vivo model organism for SARS-CoV-2-related research
potential is illustrated in Figure. A great deal of genes and
pathways now subject to intense scientific investigation
in humans and mammals were first identified in D.

Table. Categories of some human viruses studied using Drosophila as a model in vivo organism.
Name of virus/genome type

Diseases in human

Human immune-deﬁciency
virus (HIV)-1/single stranded RNA
Severe acute respiratory syndrome
coronavirus (SARS-CoV/single
stranded RNA
West Nile virus (WNV)/single
stranded RNA

Acquired immune deﬁciency Inhibition of Toll pathway and induction
syndrome (AIDS)
of JNK pathway
A typical pneumonia

Results

Possible interactions between the SARSCoV3a with cytochrome c

West Nile fever (including
Possible inhibition of RNAi in Drosophila
meningitis and encephalitis) by noncoding WNV RNA
Detected some host factors for
Inﬂuenza A virus (IAV)/single
Flu pandemics
inﬂuenza virus replication and host cell
stranded RNA
programming
Human cytomega-lovirus (HCMV)/
Inhibition of embryogenesis via viral
Birth defects
proteins
double stranded RNA
Infectious mononucleosis,
Determination of related with human
Epstein-Barr virus (EBV)/double
several types of cancer, and suppressors which focused by the BRLF1
stranded RNA
multiple sclerosis
of EBV to induce tumorigenesis

References
Leulier et al., 2003
Wong et al., 2005
Chotkowski et al.,
2008
Hao et al., 2008
Steinberg et al.,
2008
Adamson and
LaJeunesse, 2012
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Figure. Drosophila as an in vivo model organism for SARS-CoV-2-related potential research.

melanogaster. For example, the Wnt signalling pathway
in mammalians was originally detected as wingless
(wg1) recessive mutation in Drosophila leading to the
development of wingless/halterless flies (Sharma and
Chopra, 1976). At cellular level, Wnt signalling pathways
are known to be involved in a wide range of human diseases
and processes that regulate cell proliferation, morphology,
and fate determination (Korkut et al., 2009).
In unraveling the codes of human viral infections, fruit
flies have for some time been used as a model organism to
study host interactions with known pathogens, which has
taught us valuable lessons about the pathology of infection.
Drosophila models offer rapid and simple genetics allowing
a great number of studies to be conducted in a short
time that is not possible in large vertebrates or mammals
(Dionne and Schneider, 2008). With the help of such a
suitable and established model organism already used
in characterization of several viral restriction pathways
(Wang et al., 2006; Zambon et al., 2006; Chotkowski et
al., 2008), novel therapeutic agents designed to treat viral
infections can be tested in vivo in a much easier, faster, and
more economical manner. In fact, Drosophila has already
been used to investigate the impact of various viral gene
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products, including HIV-Tat-related pathogenicity, effect
of Vpu on fly immune defense, and chromosome number
aberrations induced by HIV (Battaglia et al., 2001, 2005;
Leulier et al., 2003). As known, Toll/nuclear factor-κB
(NF-κB) signalling pathways are conserved between flies
and mammals, Leulier et al. (2003) showed that a function
for Vpu in the inhibition of host NF-κB-mediated innate
immune defences and provide a powerful genetic approach
for studying Vpu inhibition of NF-κB signalling in vivo.
The HIV-1 Tat protein was first reported to bind to tubulin
in fruit fly through the MAP-binding domain of tubulin
(Battaglia et al., 2001) and this type of interaction where
HIV-1 Tat protein binds tubulin and microtubules was
later demonstrated in mammalian cells (Chen et al., 2002).
In their review paper, Spresser and Carlson concluded that
D. melanogaster could be used as a complementary model
organism in research into genetics associated with HIV-1
infection (Spresser and Carlson, 2005).
Over the past decade, Drosophila has been employed by
studies that investigate specific microbial virulence factors,
molecular characteristics, and cellular functions of viruses
relevant to human health (Hughes Amanda et al., 2012;
Panayidou et al., 2014) and host antiviral immunity in
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different animal species (Xu and Cherry, 2014; Nainu et al.,
2017). Given that all viruses depend on host cell proteins
to complete their viral life cycle, accurate detection of host
cellular factors associated with each step of SARS-CoV-2
replication can ultimately afford us a wealth of knowledge
in designing therapies for COVID-19. However, this
might take a long time with traditional genetic screening
techniques and mammalian animal models. In this
context, Hao et al. (2008) used a novel genome-wide RNAi
screen in Drosophila to identify host genes playing a role in
the replication of H5N1 and H1N1 influenza viruses. They
modified influenza virus to create infection in fly cells
and identified the gene expression of the virus, reporting
that three Drosophila genes with human homologs had
important functions in viral replication. Such an approach
could accelerate the development of novel therapeutics and
vaccines in the battle against future virus strains resistant
to available remedies (Hao et al., 2008). Furthermore,
previous work utilized GAL4/UAS (upstream activating
sequence) system to characterize gene expression and
function of SARS-coronavirus 3a protein in a transgenic
Drosophila model (Wong et al., 2005). A similar study
described the proapoptotic role of the SARS-coronavirus
M protein in fruit flies (Chan et al., 2007). Adapted by
Brand and Perrimon in 1993, the GAL4/UAS system has
been a powerful tool used for targeted gene expression
and function in Drosophila. The GAL4 system can thus be
used to study regulatory interactions during embryonic
development. In adults, targeted expression can be used to
generate dominant phenotypes for use in genetic screens.
In this landmark method, the gene that encodes the yeast
transcription factor GAL4 is inserted into the fly genome
to activate GAL4 expression, so researchers can directly
observe the impact of gene expression on immune response
pathways (Brand and Perrimon, 1993). The GAL4/UAS
system contains two parts: GAL4 under a specific promoter
in one transgenic fly line, and the target gene of interest
under the control of the UAS in another fly line. When the
two parts are in the same fly in the offspring of these flies,
GAL4 binds to the UAS driving the expression of the target
gene. Using this bipartite GAL4/UAS system, Yang et al.
(2020) recently developed and characterized a transgenic
Drosophila model to screen disease-causing SARS-CoV-2
proteins, which they reported could successfully single
out potential treatments designed to target pathogenic
viral proteins. They showed that expression of ORF3a, a
protein unique to coronaviruses, in the central nervous
system of Drosophila flies was capable of causing apoptosis
and inflammation of the nervous tissue, suggesting
ORF3a could be a key virulence factor and their ORF3a
Drosophila model reflected the main features of SARSCoV-2 infection reported in human patients (Yang et al.,
2020).

4. Potential uses of Drosophila in COVID-19 research
While transgenic Drosophila flies can be infected with
viral pathogens for experimental purposes in laboratory
settings, the wild types are also constantly infected by
bacteria or viruses in their natural environment (Ekström
and Hultmark, 2016), therefore examining the immune
responses and antiviral immunity in this model organism
could help elucidate human inflammatory processes and
enhance our understanding of antiviral defenses. Even
though Drosophila fights invasive pathogens through
a series of sophisticated defense reactions, it does not
possess an adaptive immune system, which renders
Drosophila an ideal candidate as a model to investigate
further characteristics of innate immunity that could
otherwise remain overshadowed by adaptive immune
system. Its cell-mediated innate immune response
against pathogens involves activation of relevant signal
transduction pathways, generation of antimicrobial
peptides and ROS, phagocytosis of microbial pathogens,
and encapsulation of invading elements (Salminen and
Vale, 2020). Many organisms including humans and other
vertebrates are known to exhibit similar innate defense
mechanism that constitutes the first line of defense in the
fight against microbial pathogens like bacteria and viruses
before the acquired immune system is triggered. Thanks
to the remarkable homology between the Drosophila
and human innate immune mechanisms, such as the
Toll pathway (Zambon et al., 2006), it may well be used
in the studies aimed at elucidating our immune response
to SARS-CoV-2 infection. As revealed by early research,
as soon as this virus travels through the lower respiratory
tract, a strong innate immune response is triggered, and
during this phase, patient’s immune system begins to
produce proinflammatory cytokines that result in viral
sepsis together with other severe complications (CostelaRuiz et al., 2020).
Another area of COVID-19 research where Drosophila
offers an immense potential in antiviral drug discovery
might be identification of disease-modifying targets. To
accomplish this, various novel genetic tools already exist
in our toolbox, such as GAL4 drivers that can activate
tissue-specific expression of transgenes, particularly those
found in the trachea of the fly (Liu et al., 2003). Such
strains can be utilized to drive interfering RNA units in
the Drosophila trachea to specifically inhibit expression of
genes with human homologs that have key significance for
the physiology of respiratory airways (Roeder et al., 2009).
A study using RNA interference, for example, investigated
the impact of viral infection on gene expression in wildtype Drosophila in an attempt to determine candidate genes
with possible antiviral properties (Cordes et al., 2013).
Results of this study showed that differential regulation
of genes associated with Toll and immune-deficient
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pathways, cytoskeletal development, Janus kinase-signal
transducer and activator of transcription interactions,
and a potential gut-specific innate immune response were
found (Cordes et al., 2013). In addition, further studies
that will establish the differential gene expression profile
of SARS-CoV-2 in Drosophila might help us track down
genes of interest and their functions in innate antiviral
immune response (Chan et al., 2007; Yang et al., 2020).
Such approaches offer prospects for determining and
confirming essential components of respiratory function
that may point to druggable proteins or nucleic acids, or
drug targets, in the treatment of respiratory diseases like
COVID-19 (Pandey and Nichols, 2011). There is, however,
rather limited research on using Drosophila as a model
organism to screen vaccine candidates or therapies for
COVID-19, but we have all the necessary biological tools
ready and available for such an endeavour, particularly
including the revolutionary CRISPR gene-editing systems
(Chan et al., 2007; Yang et al., 2020).
5. Potential use of CRISPR gene-editing systems against
COVID-19
As soon as the causative viral agent of COVID-19 was
discovered, many scientists engaged in gene-editing
efforts shifted their focus on the global battle against
the pandemic. The current challenge facing researchers
from diverse fields of science and technology is how to
optimize and streamline gene-editing systems in creating
better solutions. A groundbreaking discovery in the
field of genetics, CRISPR associated with Cas9 systems
have recently gained huge recognition in the scientific
community, as they can give rise to a variety of applications
in gene targeting and genome editing (Jinek et al., 2012).
The multifaceted CRISPR gene-editing system allows
modifications in the genes of both microbial pathogens
and hosts such as gene deletions or site-specific gene
insertions, as well as investigation of mechanisms involved
in the development of infection, hence a versatile weapon
against viruses and bacteria that rapidly evolve resistance.
In fact, CRISPR-based approaches have already shown
huge promise in identifying new therapeutic targets
for the Plasmodium parasites that cause malaria (Lee et
al., 2019), characterizing key bacterial virulence genes
causing tuberculosis (Singh et al., 2016; Choudhary et
al., 2019), and programming nucleases to kill pathogenic
bacteria like E. coli and Salmonella (Hamilton et al.,
2019). More importantly, Bikard et al. (2014) showed that
RNA-guided nuclease could be programmed to target
antibiotic resistance genes in a major bacterial human
pathogen (Staphylococcus aureus) that causes pneumonia,
skin and bone infections, reporting that CRISPR-Cas9
antimicrobials also functioned in vivo to destroy the
bacteria in mice. After their detailed review of latest
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research into applications of CRISPR-Cas9, Doerflinger
et al. (2017) concluded that this gene-editing technology
was a valuable tool to produce streamlined antimicrobials
against drug‐resistant strains of bacteria and to kill such
pathogens with their own weapons.
6. CRISPR-based diagnostic tools
Considering that the mechanism was initially developed
in bacterial genomes as a technique to disable RNA
viruses, it is only natural that it will be transformed into a
valuable tool to create rapid diagnostic tools and antiviral
therapeutics. PCR-based COVID-19 testing is currently
the primary method of diagnostic procedures across
the globe; however, it requires a relatively long wait for
results, sophisticated equipment, and technical expertise,
which calls for alternative testing options, as rapid and
ultrasensitive population-wide screening is vital to
controlling the spread of infection. Accordingly, a recent
study provided a series of assay design options ideal for
use with CRISPR systems in the testing of SARS-related
coronaviruses, as well as detection of 67 virus species,
including influenza and rhinoviruses (Metsky et al., 2020).
Researchers combining CARMEN pathogen detection
platform and CRISPR-Cas13 method (CARMENCas13) managed to develop a mass testing technique that
screens over 4500 crRNA-target pairs through a single
array. Their novel method can identify newly discovered
pathogens like SARS-CoV-2 and has the potential to
reduce the cost of testing substantially (Ackerman et al.,
2020). In this technology (CARMEN), nanolitre droplets
containing CRISPR-based nucleic acid detection reagents
self-organize in a microwell array to pair with droplets
of amplified samples, testing each sample against each
CRISPR RNA (crRNA) in replicate. The combination
CARMEN-Cas13 enables robust testing of more than
4500 crRNA-target pairs on a single array (Ackerman
et al., 2020). Such multifaceted and scalable CRISPRbased diagnostic approaches could transform selective
COVID-19 surveillance efforts into mass testing programs
and help alleviate the current strain on health systems,
as lack of accurate and rapid population-wide testing for
SARS-CoV-2 still remains a challenge. In this regard, a new
study has proposed a rapid and sensitive assay that uses
CRISPR-Cas12a activity to detect SARS-CoV-2 in patient
saliva in 15 min (Ning et al., 2020). CRISPR diagnostics
could also be used to augment PCR-based testing, as
demonstrated by a recent CRISPR-Cas13a-based test
developed to detect SARS-CoV-2 directly in nasal swab
RNA that can be read through a mobile phone camera
(Fozouni et al., 2021). These different advances using
CRISPR-Cas systems underscore their great potential in
the development of rapid and accurate tests for COVID-19
and other infectious diseases that may emerge in the future
(Xiang et al., 2020).
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7. CRISPR-based antiviral therapeutics
Efforts to design and develop CRISPR-based therapeutics
for infectious disease by modifying susceptible host genes
or virus genes regulating replication have recently gained
a significant momentum. The potential of CRISPR-Cas9
gene-editing system as a promising tool in treating and
preventing HIV infection was shown in early research
(Ebina et al., 2013). Another study reported that CRISPRCas9 system could be adapted for an effective antiviral
therapy in human cells by targeting the viral genes
associated with life-long persistent infections caused
by herpes simplex viruses (Wang and Quake, 2014).
Certain CRISPR effectors could be reprogrammed to
combat against viral infections, as previous research
revealed that they could inhibit replication of viruses
in infected mammalian cells (Yin et al., 2017; Ophinni
et al., 2018; Wang et al., 2018). For example, Cas13a,
guided by CRISPR RNAs, was programmed to target
respiratory syncytial virus and influenza virus in human
cells and shown to treat and prevent such infections, with
possibility of mRNA-powered antiviral interventions
(Bawage et al., 2018). In vivo applications utilizing
CRISPR-Cas13 for targeting RNA viruses to mitigate their
infectivity have been suggested to pave the way for novel
antiviral treatments for a wide range of viral diseases,
including influenza and COVID-19 (Freije et al., 2019).
Meanwhile, a team of researchers has recently developed
a prophylactic antiviral intervention, adopting a novel
CRISPR-Cas13-based approach will attack all known
coronavirus species, including SARS-CoV-2, to achieve
an aggressive pan-coronavirus protection (Abbott et al.,
2020). Initially performing experiments designed to target
influenza A virus (IAV) in human lung epithelial cells,
the team refocused their efforts on testing their approach,
called PAC-MAN, in SARS-CoV-2, to join the global battle
against COVID-19 pandemic. However, despite its worth
as a molecular approach in vitro, the major challenge here
is whether we can translate research into clinical practice
for potential COVID-19 therapies or vaccines, for we
urgently need an effective in vivo method to safely deliver
it to target cells in the lungs (Abbott et al., 2020). To that
end, suitable and versatile model organisms are required in
preclinical trials to validate the immunogenicity induced
by CRISPR-based therapies (Mehta and Merkel, 2020).
Through experiments with a highly suitable in vivo model
like D. melanogaster, for example, the efficacy of novel
therapeutics developed by CRISPR genome editing can
be swiftly investigated prior to testing in higher vertebrate
systems.
8. Use of Drosophila as a model in CRISPR-based
solutions
The rapid rise of gene-editing systems has stirred public
and academic debate over the ethical implications of using

such methods in mammalian models in terms of animal
welfare, risks, and uncertainty (De Graeff et al., 2019),
because some CRISPR-based applications may still have
insufficient efficiency in gene targeting, which can lead
to unintended genetic modifications or mosaic mutations
(Mehravar et al., 2019). Although limited in amount,
there has been some research into CRISPR-mediated in
vivo genetic screens using different animal models, such
as mice (Chen et al., 2015; Manguso et al., 2017) and
zebrafish (Shah et al., 2015). However, these experiments
often involve complex and lengthy procedures that may
restrict the scope and efficiency of mutation analyses.
In this context, researchers can rely on a better
candidate known for its suitability for genetic screens: D.
melanogaster. It has been employed as a highly efficient
in vivo model in endogenous CRISPR-based genome
modifications, such as gene insertions, deletions, and
precise sequence edits (Gratz et al., 2015). Previously,
Bassett et al. (2013) reported that they developed an easy
and efficient CRISPR-Cas9 method to induce and monitor
the mutagenesis of target genes in Drosophila with an
impressive 10-fold in efficiency. Several other studies
confirmed the speed and efficiency of Drosophila model in
CRISPR-based genome-editing systems (Kondo and Ueda,
2013; Ren et al., 2013; Gratz et al., 2014; Port et al., 2014;
Gratz et al., 2015). Besides, more recent research has shown
that tissue-specific genome editing with CRISPR system
(tsCRISPR) can be successfully applied in Drosophila
to keep mutations limited to intended tissue or group of
cells (Meltzer et al., 2019). This type of high-efficiency
targeted gene modification in Drosophila was achieved by
utilizing the bipartite GAL4/UAS system in combination
with CRISPR-Cas9 method (Gratz et al., 2014). The use
of tissue-specific CRISPR in Drosophila offers great
promise in facilitating high-throughput in vivo screening,
along with a great potential to overcome the restrictions
of currently available screening methods (Meltzer et
al., 2019). Genome-editing efforts often cause off-target
alterations that may change the expression of otherwise
intact genes or disrupt vital coding regions, which might
induce genotoxicity (Fu et al., 2013; Eid and Mahfouz,
2016). In addition, epigenetic CRISPR therapeutics has
also been reported to induce serious off-target effects
causing dysfunction in a series of biological pathways,
including innate immune responses (Khan et al., 2016).
Nevertheless, such unintended off-target activities should
pose no great concern in Drosophila, for they can be easily
monitored in vivo throughout several generations thanks
to its short life cycle.
One of the most critical challenges currently
complicating CRISPR systems is the lack of efficient
delivery methods that would transport CRISPR-Cas9
components into desired cells, and nanoparticles present
a range of advantages over other delivery methods, which
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include high efficiency, fine-tuning of particle size, low
immunogenicity and mutagenicity nanosized particles
(Rahimi et al., 2020). In this regard, Drosophila once again
stands out asa familiar and highly efficient model gaining
popularity in recent research into nanoparticle toxicity
and genotoxicity (Demir, 2020), and it has the potential
to facilitate and accelerate the testing of nanobased
CRISPR delivery methods. Besides, the long-term impacts
of CRISPR-based therapeutics for viral infections like
COVID-19 on several biochemical pathways conserved
within humans can also be studied in Drosophila much
faster than in other in vivo models. Huynh et al. (2020)
showed that a CRISPR-based technology, Cas13 works
efficiently in Drosophila, both ex vivo and in vivo. Like Cas9,
Cas13 uses a guide RNA (CRISPR-RNA, 57 aka crRNA)
to identify its substrate, that is RNA rather than DNA.
Cas13 may have far-reaching implications for simplifying
diagnostics. To develop a fast test for COVID-19, the
specific high-sensitivity enzymatic reporter unlocking
(SHERLOCK) protocol, a recently developed Cas13-based
diagnostic test for infectious diseases, can detect the virus
in 50 min (Gootenberg et al., 2018; Kellner et al., 2020).
In another study, CRISPR/Cas13 was also used to detect
SARS-CoV-2 (Metsky et al., 2020). These studies promise
that important potential of Cas13 as a diagnostic and
therapeutic tool. Screening the efficacy of antiviral agents
or vaccines in a whole living organism without ethical
considerations allows quick selection of compounds with
better safety profiles before conducting preclinical tests in
relatively expensive mammalian models.
9. Future perspectives
As part of mass vaccination campaigns in an effort to
tackle the escalating COVID-19 pandemic, multiple
countries have been allowing antiviral vaccines under
emergency use authorization, while multiple candidate
vaccines are either being tested in humans or scheduled
for preclinical evaluation. In the meantime, new variants

of SARS-CoV-2 with unusually large number of mutations
are constantly detected across the globe (Galloway,
2021), thus we urgently need flexible and easily adaptable
technologies like CRISPR-based systems to develop
effective pan-coronavirus solutions as a quick response to
pandemics. Even if the intensive global effort currently put
in COVID-19 research fails to produce a clinically viable
therapeutic option for the current pandemic, CRISPR will
emerge victorious in the battle against future viral and
bacterial infections. Once the limitations like off-target
effects and delivery issues have been resolved, CRISPRbased therapeutics may represent another momentous
step forward in public healthcare. And with its versatile
features suitable for multiple roles in rapid and accurate
testing, D. melanogaster could become a strong ally in
our fight against various infectious agents. Angiotensinconverting enzyme-related (ACER) gene is the Drosophila
ortholog of mammalian ACE2 (Liao et al., 2014). As
commonly known, mammalian ACE2 arranges cardiac
contractility mainly, while Drosophila ACER arranges
heart development during embryogenesis (Crackoweret
et al., 2002). In addition, ACER also probably arranges
the heart physiology in adult flies as it is expressed in the
heart of Drosophila during development (Houardet et al.,
1998). Strategies targeting the use of this ortholog gene
can be developed using a variety of genome engineering
techniques and thus valuable fly model can be developed
and used for COVID-19-related research. Even though all
scientific attention is currently directed towards creating
quick solutions that will end the pandemic and bring life
back to normal, we should note that the advances made
in gene-editing technology as part of this process will be
applicable to a multitude of infectious diseases and future
pandemics.
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